Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Rheumatology and Therapy
Published in: Rheumatology and Therapy 1/2018

Open Access 01-06-2018 | Case Report

A Case Report of Chikungunya Fever, Rheumatoid Arthritis, and Felty’s Syndrome

Authors: José Kennedy Amaral, Robert T. Schoen

Published in: Rheumatology and Therapy | Issue 1/2018

Login to get access

Abstract

Introduction

Chronic chikungunya (CHIK) arthritis, an inflammatory arthritis, often follows acute CHIK fever (CHIKF), a viral infection. The pathogenesis of chronic CHIK arthritis is poorly characterized, but may resemble other forms of inflammatory arthritis. Clinically, chronic CHIK arthritis sometimes mimics rheumatoid arthritis (RA).

Case Report

We report a patient with well-characterized CHIKF followed 2 months later by chronic CHIK arthritis not only resembling RA clinically, but also associated with RA biomarkers and extra-articular features, including Felty’s syndrome (FS).

Conclusions

We describe this patient’s excellent response to methotrexate and discuss the implications her case provides in understanding this important emerging rheumatic disease.
Literature
1.
Yactoyo S, Staples JE, Millot V, Cibrelus L, Pardo PR. Epidemiology of chikungunya in the Americas. J Infect Dis. 2016;214(5):441–5.CrossRef
2.
3.
Amaral Pereira J, Kennedy Schoen RT. Management of chikungunya arthritis. Clin Rheumatol. 2017;36:2179–86.CrossRef
4.
Miner JJ, Aw Yeang HX, Fox JM, Taffner S, Malkova ON, Oh ST, et al. Brief report: chikungunya viral arthritis in the united states: a mimic of seronegative rheumatoid arthritis. Arthritis Rheumatol. 2015;67:1214–20.CrossRefPubMedPubMedCentral
5.
Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2010;51(suppl 6):vi5–9.
6.
Bagher Owlia M, Newman K, Akhtari M. Felty’s syndrome, insights and updates. Open Rheumatol J. 2014;8:129–36.CrossRef
7.
Rodríguez-Morales AJ, Cardona-Ospina JA, Fernanda Urbano-Garzón S, Sebastian Hurtado-Zapata J. Prevalence of post-chikungunya infection chronic inflammatory arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2016;68:1849–58.CrossRef
8.
9.
Chopra A, Anuradha V, Lagoo-Joshi V, Kunjir V, Salvi S, Saluja M. Chikungunya virus aches and pains: an emerging challenge. Arthritis Rheumatol. 2008;58:2921–2.CrossRef
10.
Jaller Raad J, Segura Rosero A, Vidal Martínez J, Parody A, Jaller Raad R, Caballero Tovar D, et al. Immunological response of a population from the Caribbean region of Colombia infected with the chikungunya virus. Revista Colombiana de Reumatología (English Edition). 2016;23:85–91.
11.
Schilte C, Staikowsky Couderc T, Madec Y, Carpentier F, Kassab S, et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis. 2013;7:e2137.CrossRefPubMedPubMedCentral
12.
Jaffar-Bandjee MC, Das T, Hoarau JJ, Krejbich Trotot P, Denizot M, Ribera A, et al. Chikungunya virus takes centre stage in virally induced arthritis: possible cellular and molecular mechanisms to pathogenesis. Microbes Infect. 2009;11:1206–18.CrossRefPubMed
13.
Chang A, Martins K, Encinales L, Reid SP, Acuña M, Encinales C, et al. (2017) Cross-sectional analysis of chikungunya arthritis patients 22-month post-infection demonstrates a lack of viral persistence in synovial fluid [abstract]. Arthritis Rheumatol 69(suppl 10) (Chang A, Martins K. Contributed equally).
14.
Venebles PJW, Maini RN. Diagnosis and differential diagnosis of rheumatoid arthritis. In: Romain PL editor. UptoDate. 2017.
15.
Taylor PC, Maini RN. Biomarkers in the diagnosis and assessment of rheumatoid arthritis. In: Romain PL editor. UptoDate. 2018.
16.
Felty AR. Chronic arthritis in the adult associated with splenomegaly and leukopenia. Bull Johns Hopkins Hosp. 1924;35:16.
17.
Kay J. Clinical manifestations and diagnosis of Felty’s syndrome. In: Romain PL editors. UptoDate. 2018.
18.
Cavalcanti LP, Freitas AR, Brasil P, Cunha RV. Surveillance of deaths caused by arboviruses in Brazil: from dengue to chikungunya. Memórias do Instituto Oswaldo Cruz. 2017;112:583–5.CrossRefPubMedPubMedCentral
19.
Goldberg J, Pinals RS. Felty’s syndrome. Semin Arthritis Rheumatol. 1980;10:52–65.CrossRef
20.
Martí-Carvajal A, Ramon-Pardo P, Javelle E, Simon F, Aldighieri S, Horvath H, et al. Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: a systematic review. PLoS One. 2017;12:e0179028.CrossRefPubMedPubMedCentral
21.
22.
Ravindran V, Alias G. Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24 week randomized controlled open label study. Clin Rheumatol. 2017;36:1335–40.CrossRefPubMed
23.
Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty’s syndrome. Br J Rheumatol. 1998;37:908–11.CrossRefPubMed
Metadata
Title
A Case Report of Chikungunya Fever, Rheumatoid Arthritis, and Felty’s Syndrome
Authors
José Kennedy Amaral
Robert T. Schoen
Publication date
01-06-2018
Publisher
Springer Healthcare
Published in
Rheumatology and Therapy / Issue 1/2018
Print ISSN: 2198-6576
Electronic ISSN: 2198-6584
DOI
https://doi.org/10.1007/s40744-018-0103-9

Other articles of this Issue 1/2018

Rheumatology and Therapy 1/2018 Go to the issue

Original Research

Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis

Original Research

Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data

Original Research

Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United States

Commentary

Living with Juvenile Idiopathic Arthritis: Parent and Physician Perspectives

Original Research

Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study

Case Report

A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits